Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Astellas VP-Business Development Masaki Doi: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

Japanese pharma exec discusses Astellas’ global licensing strategy, the FibroGen deal, and the changing paradigm of Japanese deal flow.

You may also be interested in...



Astellas Sees Further FDA Action On Prograf MR In Early 2008

Astellas responded in July to an "approvable" letter received in January for use of the immunosuppressant Prograf MR (tacrolimus) in liver transplantation, the Japanese pharma revealed during its first quarter 2007 earnings call August 1

Astellas Sees Further FDA Action On Prograf MR In Early 2008

Firm and partner FibroGen also plan response to FDA’s clinical hold on their novel EPO candidates by year end.

Astellas Sees Further FDA Action On Prograf MR In Early 2008

Firm and partner FibroGen also plan response to FDA’s clinical hold on their novel EPO candidates by year end.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS065865

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel